Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN 70 30 PEN versus HUMULIN R KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN 70 30 PEN versus HUMULIN R KWIKPEN.
HUMULIN 70/30 PEN vs HUMULIN R KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro and insulin lispro protamine suspension. Insulin lispro lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production. Insulin lispro protamine provides intermediate-acting basal coverage.
Insulin lispro lowers blood glucose by binding to insulin receptors, increasing glucose uptake in skeletal muscle and adipose tissue, and inhibiting hepatic glucose production.
Subcutaneous injection, individualized based on metabolic needs and blood glucose monitoring; typical starting dose for type 1 diabetes: 0.5 to 0.6 units/kg/day in divided doses (usually twice daily with 70% intermediate-acting NPH and 30% regular insulin); for type 2 diabetes: 0.2 units/kg/day initially, adjusted per glycemic response.
Subcutaneous injection, individualize based on metabolic needs and blood glucose monitoring. Typical starting total daily insulin dose in type 1 diabetes: 0.5-1 unit/kg/day, with 50-60% as basal and 40-50% as prandial. In type 2 diabetes, initial total daily dose: 0.2-0.4 units/kg/day, with adjustments. Administer 30 minutes before meals.
None Documented
None Documented
The terminal elimination half-life of insulin in Humulin 70/30 is approximately 1.5 hours for the regular insulin component and 4-6 hours for the NPH component due to protamine suspension, resulting in a prolonged duration of action.
5-10 minutes (intravenous); subcutaneous: 1.5-2 hours (depot absorption-limited).
Insulin is primarily eliminated via renal metabolism and excretion; approximately 30-80% is cleared by the kidneys, with the remainder undergoing hepatic metabolism. Biliary/fecal excretion is negligible (<1%).
Renal: 60-80% (metabolized to inactive peptides); hepatic metabolism via insulin-degrading enzyme; remainder reabsorbed in proximal tubule.
Category C
Category C
Human Insulin
Human Insulin